glp-1 substance use disorder GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and intake, though GLP-1 receptor agonists show promise

More than 4 million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/2026 1 , while around 2.5 million people each month accessed GLP-1s privately at the end of 2025, according to James Kingsland, chair of the Digital Clinical Excellence (DiCE) network of primary care digital health providers

(Week-by-Week Timeline) How Long Does Semaglutide Take to Work

However, the lower dose of semaglutide used and a focus on patient-reported outcomes rather than on cardiovascular events are limitations of STEP-HFpEF DM

Many people turn to skin-brightening creams or serums to improve their complexion but these topical solutions often fall short

Endocrine disrupting chemicals: effects on endocrine glands